Approval

Brazil clears Henlius' HLX11, its first pertuzumab biosimilar, for HER2+ breast cancer

Anvisa approved HLX11 in combination regimens for metastatic or unresectable locally recurrent HER2-positive breast cancer and for eligible patients before or after surgery. The decision drew on analytical and pharmacokinetic work plus a comparative clinical study. Henlius developed the biosimilar, and Organon holds commercial rights outside China.

Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call